{{'2024-10-21T09:26:27Z' | dateFormatFilter}}
Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
Read more
{{'2024-10-18T09:32:29Z' | dateFormatFilter}}
Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
Read more
{{'2024-10-08T08:00:44Z' | dateFormatFilter}}
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
Read more
Progress towards zero environmental impact
Being respected for adding value to society
Ensure distinct core capabilities and evolve culture
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD
Strengthen Diabetes leadership - aim at global value market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Deliver solid sales and operating profit growth:
Drive operational efficiencies across the value chain to enable
investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Investors
Share price
{{priceData.date}} {{priceData.time}}